Coya Therapeutics, Inc. (COYA) — Financial statements
Income statement, balance sheet, and cash flow for Coya Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 8↑123.6% | 4↓40.8% | 6 | 0.00 | 0.00 | |
| Cost of Revenue | 0.03↓99.8% | 12↑115.7% | 6↑24.7% | 4 | 0.00 | |
| Gross Profit | 8↑195.3% | -8↓1760.1% | 0.50↑111.3% | -4 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 17↑40.7% | 12↑96.7% | 6↑22.4% | 5↑94.2% | 3 | |
| General & Administrative Expenses | 11↑28.9% | 9↑13.4% | 8↑61.6% | 5↑109.6% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↑28.9% | 9↑13.4% | 8↑61.6% | 5↑109.6% | 2 | |
| Other Expenses | 0.00↑100.0% | -12↓116.3% | -5↓24.8% | -4↓27281.2% | 0.02 | |
| Operating Expenses | 28↑215.3% | 9↑6.4% | 8↑55.6% | 5↑10.9% | 5 | |
| Total Costs & Expenses | 28↑35.6% | 21↑49.6% | 14↑41.7% | 10↑101.5% | 5 | |
| Operating Results | ||||||
| Operating Income | -20↓17.5% | -17↓118.3% | -8↑19.5% | -10↓101.5% | -5 | |
| Depreciation & Amortization | 0.03↑0.0% | 0.03↑0.0% | 0.03↑0.0% | 0.03↑69.6% | 0.02 | |
| EBITDA | -20↓17.7% | -17↓134.5% | -7↑20.8% | -9↓90.8% | -5 | |
| EBIT | -20↓17.7% | -17↓134.0% | -7↑20.7% | -9↓90.7% | -5 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.03↑95.4% | -0.54↓3.5% | -0.53 | 0.00 | |
| Other Income / Expenses | -0.96↓158.1% | 2↑157.9% | 0.64↑126.3% | -2↓11225.0% | -0.02 | |
| Income Before Tax | -21↓36.0% | -16↓114.8% | -7↑40.7% | -12↓150.3% | -5 | |
| Income Tax Expense | 0.00↑100.4% | -0.72↓199.5% | 0.72 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↓42.6% | -15↓86.3% | -8↑34.8% | -12↓150.3% | -5 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↓42.6% | -15↓86.3% | -8↑34.8% | -12↓150.3% | -5 | |
| Bottom-Line Net Income | -21↓42.6% | -15↓86.3% | -8↑34.8% | -12↓150.3% | -5 | |
| EPS (Basic) | -1.27↓29.6% | -0.98↓24.1% | -0.79↑35.8% | -1.23↓66.3% | -0.74 | |
| EPS (Diluted) | -1.27↓29.6% | -0.98↓24.1% | -0.79↑35.8% | -1.23↓66.3% | -0.74 | |
| Weighted Average Shares | 17↑9.8% | 15↑49.9% | 10↑2.2% | 10↑50.7% | 7 | |
| Weighted Average Diluted Shares | 17↑9.8% | 15↑49.9% | 10↑2.2% | 10↑50.7% | 7 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.